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Introduction
Peroxisome proliferator-activated receptors  (PPAR) are ligand-activated transcription factors of the nuclear hormone receptor superfamily known to be involved in adipogenesis, glucose homeostasis, inflammatory responses and apoptosis (Michalik et al., 2006) .
Endogenous ligands of PPAR include fatty acids and prostaglandin-type eicosanoids like 15-deoxy-Δ 12-14 -PGJ 2 . However, the best known PPAR agonists are the thiazolidinediones (TZD), e.g. pioglitazone (Pio), rosiglitazone (Rosi) and ciglitazone, which comprise a class of synthetic drugs that are FDA-approved and are widely used for the treatment of type II diabetes. These drugs induce a complex response involving both binding of the PPAR to peroxisome proliferator response elements (PPRE) and various mechanisms that are independent of DNA binding. Moreover, structurally different PPAR agonists are known to induce both common and selective responses (Gervois et al., 2007) .
Thiazolidinediones are now also emerging as novel therapeutic agents in other diseases, including cancer, arthritis and inflammatory and renal diseases (Guan and Breyer, 2001; Ialenti et al., 2005; Koeffler, 2003; Yang et al., 2009) . They have been shown to reduce proteinuria, microalbuminuria and podocyte injury in both diabetic nephropathy and non-diabetic glomerulosclerosis in mouse and rat models, as well as in humans (Cha et al., 2007; Ma et al., 2001; Sarafidis et al., 2010; Yang et al., 2006) . In addition, Pio has been shown to provide protective effects against progression of puromycin aminonucleoside (PAN)-induced glomerulosclerosis in vivo and also in an in vitro model using cultured podocytes (Kanjanabuch et al., 2007; Yang et al., 2006) . Rosi has also been reported to attenuate proteinuria and glomerulosclerosis in adriamycin-induced focal segmental glomerulosclerosis in rats (Liu et al., 2010) . Based in part on this, Rosi successfully passed a phase I safety trial (Joy et al., 2009) , and was scheduled for a Phase II clinical trial as a treatment for this kidney disease until being withdrawn from study due to new safety concerns (Peyser et al., 2010) 
. Despite this, in a recent
This article has not been copyedited and formatted. The final version may differ from this version. 5 meta-analysis it was concluded that TZDs significantly decrease albuminuria and proteinuria in patients with diabetes, and suggested that they may do so by providing direct renoprotective effects (Sarafidis et al., 2010) .
Nephrotic syndrome (NS) is one of the most common kidney diseases seen in children and adults. It is a remitting and relapsing disease characterized by massive loss of serum proteins into the urine through a damaged glomerular filtration barrier, leading to hypoalbuminemia and swelling throughout the body (edema) (Smoyer and Mundel, 1998) . Podocytes are a key component of the kidney's filtration barrier, and during NS they undergo dramatic structural alterations in the foot processes that attach these cells to the glomerular basement membrane.
The most widely accepted experimental models used to mimic the podocyte injury that occurs during NS in humans include PAN injection of rats (Pippin et al., 2009 ) and PAN treatment of cultured podocytes (Ransom et al., 2005) . For the last 50 years the primary therapy for NS has been oral glucocorticoids (GC). Unfortunately, GCs have serious side effects, and in ~20% of patients they are ineffective in inducing clinical remission of disease (i.e. steroid resistant NS).
Thus it is clear that alternative therapies with greater efficacy and/or less severe side effects are critically needed (Hodson and Craig, 2008) .
Based on the well-established, but poorly understood, renal protective effects of thiazolidinediones, we hypothesized that their protection results, at least in part, from their direct action on podocytes, similar to GCs. To test this hypothesis we compared the ability of Pio and Rosi to protect podocytes from PAN-induced injury to the known protective effects of dexamethasone (Dex) (Ransom et al., 2005; Xing et al., 2006) . Additionally, given the recentlyreported roles of various mitogen-activated protein kinases (MAPK) in kidney diseases (Grande and Lopez-Novoa, 2008) , and the known ability of PPAR agonists to regulate MAPK activities in other cell types (Gardner et al., 2005) , we also analyzed the ability of Rosi, Pio and Dex to alter MAPK activation in podocytes. Furthermore, since TZDs have recently been reported to act as partial agonists to the glucocorticoid receptor (GR) (Ialenti et al., 2005; Matthews et al., This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Cell Culture. The conditionally immortalized mouse podocyte cell line MPC-5 was cultured as described previously (Smoyer and Ransom, 2002) . Podocytes were cultured under proliferating conditions in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA) and 10 U/ml mouse -interferon (Sigma, St Louis, MO) at 33°C in a humidified atmosphere of 5% CO 2 .
Differentiation was induced by shifting the cells to 37°C in the same medium without -interferon for 10 to 14 days on culture plates (Greiner, Monroe, NC) coated with rat tail collagen type I (BD Biosciences, Bedford, MA). Human embryonic kidney epithelial cells (HEK 293T) were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO 2 . Podocytes were treated with puromycin aminonucleoside (Sigma), rosiglitazone (Fisher HealthCare, Houston, TX), pioglitazone (Enzo Life Sciences International Inc., Plymouth Meeting, PA) or dexamethasone (Sigma) as indicated in complete or serum-free medium, or in medium containing charcoal-stripped FBS (Invitrogen) at 8%. Pre-treatments or short-term treatments were performed for 4 h followed by washing and medium change. Simultaneous or long-term treatments were performed for the entire length of the experiment, until the assay or extraction.
Use of PPAR and GR antagonists. Where indicated, cells were pre-incubated 1 h prior to the addition of PPAR and GR agonists, with 10 M GW9662 (a PPAR antagonist), 10 M RU486 (a GR antagonist) or 10 M CORT108297 (a highly selective GR antagonist). GW9662 (Sigma) is an irreversible and selective PPAR antagonist which is 10-and 600-fold less potent in binding PPAR and PPAR, respectively. RU486 (Sigma) is a potent GR antagonist, although with limited specificity as it also binds to the progesterone receptor. RU486 has a K i = 0.4 nM in GR binding assays, and a K i = 1.5 nM This article has not been copyedited and formatted. The final version may differ from this version. (Clark, 2008; Clark et al., 2008) . RU486 exhibits partial agonistic activities (Matthews et al., 2009 ). CORT108297 (synthesized by Ricerca Biosciences, Concord, OH, and obtained from Corcept Therapeutics, Menlo Park, CA) is a highly selective antagonist of the GR compared to the progesterone, estrogen, androgen, and mineralocorticoid receptors, as shown in binding assays . It has also been found inactive for PPAR binding (R. Clark, Corcept Therapeutics, personal communication). CORT108297 has a K i = 0.9 nM in GR binding assays and a K i = 6.8 nM in functional GR antagonist assays (Clark, 2008; Clark et al., 2008) . It also exhibits a partial agonist activity which is higher than that of RU486 (R. Clark, personal communication).
Viability Assays. Differentiated podocytes were either pre-treated for 4 h with the vehicle dimethyl sulfoxide (DMSO), Rosi, Pio and/or Dex followed by PAN treatment (5 g/ml), or simultaneously treated with these reagents and PAN (5 g/ml) at concentrations specified in the 'Results' section. Viability assays were performed after 3 or 5 days of treatments. Briefly, cells were washed with phosphate-buffered saline (PBS), incubated in medium containing methylthiazolyldiphenyl-tetrazolium bromide (MTT; Sigma) at 500 g/ml for 4 h and the MTT formazan crystals were extracted in DMSO containing 0.01M glycine and 0.01 M NaCl (pH 10.5). Absorbance was measured at 570 nm with the reference wavelength of 630 nm on a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA). Positive control cells (100% viable) did not receive any PAN treatment while cells treated for 20 min with 0.01% Triton X-100 were used as negative controls (0% viable).
Actin Staining and Microscopy. Differentiated podocytes were cultured on cover-slips and pre-treated with vehicle, 100 M Rosi, 1 M Pio or 1 M Dex for 4 h. Following treatment, cells were washed and cultured for another 5 days with the medium containing PAN at 5 g/ml. harvested and total RNA extracted using the RNeasy kit (Qiagen, Germantown, MD). Purity and yield were determined by measuring the absorbance at 260 and 280 nm. 1 g of RNA was subjected to DNase (Ambion, Austin, TX) treatment at 37°C for 30 min followed by a DNase inactivation step in the presence of 5 mM EDTA at 75°C for 10 min. cDNA was prepared from 1 g DNase-treated RNA in a 20 l reaction using iScript reverse transcriptase (Bio-Rad) at reaction conditions of 5 min at 25°C, 30 min at 42°C followed by 5 min at 85°C. FKBP51, GILZ and -actin mRNA levels were measured by real time PCR using SYBR green and an iQ5 thermal cycler (Bio-Rad). Polymerase chain reaction (PCR) conditions were as follows: 1st cycle at 95°C for 3 min, 40 cycles at 95°C for 10 s and 55°C for 10 s followed by a melt curve analysis. The primers used for the amplification are listed in Table 1 significance ( Fig. 1B) . Similarly, combined treatment of Rosi with Dex also tended to provide better protection than Dex alone (data not shown). Viability values greater than 100% with some treatments indicated continued cell proliferation compared to controls.
These data together suggest that both TZDs exhibit the capability to protect podocytes from PAN-induced injury.
Rosi and Pio Prevent PAN-Induced Podocyte Actin Cytoskeletal Disruption. The podocyte foot processes which are disrupted during NS are well known to contain prominent actin filaments (Ransom et al., 2005; Smoyer and Mundel, 1998) . Similarly, cultured podocytes contain a distinct actin cytoskeleton with bundles of filamentous actin fibers spanning across the cell body (stress fibers), which can be visualized with Texas Red-labeled phalloidin (Fig. 2, panel A). Podocyte injury and recovery in vitro have been well-documented to involve extensive reorganization of actin cytoskeleton (Ransom et al., 2005; Smoyer and Mundel, 1998) . PAN treatment (5g/ml for 5 days) resulted not only in a reduced cell number, but also in the substantial loss of the filamentous actin in the remaining cells (panel B). Pre-treatment with Rosi (100 μM) or Pio (1 μM) preserved podocyte filamentous actin, in addition to the cell numbers, similarly as did pre-treatment with Dex (1 μM) (panels C-E). However, after pretreatment with either TZD the organization of these actin fibers was somewhat different from control cells, with relatively more filamentous actin being located in sub-cortical ring-like structures. This was especially evident after pretreatment with Pio (panel D).
Rosi Attenuates MAPK Signaling in Podocytes. PPAR agonists have been reported to elicit 'non-genomic', receptor-independent effects in addition to their well-documented role in inducing transcription of target genes in a PPAR-dependent manner. The rapid alteration of MAPK activities by Rosi and Pio previously observed in several cell types provides an example of such 'non-genomic' effects (Gardner et al., 2005) . Based on this, we tested the ability of Rosi and Pio and compared it with Dex to alter the activation of the major MAPKs, including p38
This article has not been copyedited and formatted. The final version may differ from this version. by immuno-blotting using antibodies specific for the phosphorylated (activated) and total forms of these protein kinases (Fig. 3A) . The semi-quantitative densitometric evaluation of these gels is shown in the plots of In summary, deactivation of the various MAPKs in podocytes appeared to be a selective property of Rosi as compared with Pio, although Dex also modestly deactivated ERK1/2 and p38 MAPK as well.
Rosi and Pio Increase the GR Phosphorylation in Podocytes.
The GR has been shown to undergo rapid down-regulation and phosphorylation on Ser 211 in response to GCs, and phosphorylation at this site is believed to be associated with activation of the GR (Tasker et al., 2006) . Recently, PPAR ligands have been reported to exert 'off-target' effects involving seemingly unrelated molecules and receptors, including the GR (Ialenti et al., 2005; Matthews et al., 2009 ). Recent studies have also shown that the PPAR and GR may interact directly upon PPAR activation, suggesting cross-talk between the two signaling pathways (Lahiri et al., 2009; Nie et al., 2005) . To determine if Rosi and Pio exert some of their effects in podocytes by modulating the expression or phosphorylation of the GR, we measured the total amount of the GR and its phosphorylation in podocytes treated with Rosi and Pio, and compared these responses to that of Dex (Fig. 4A) . As seen after 4 h of treatment, Dex induced down-regulation of the GR and enhanced its phosphorylation, similarly as has been previously reported (Guess This article has not been copyedited and formatted. The final version may differ from this version. In order to dissect if the phosphorylation of the GR by Rosi and Pio is PPAR and/or GRmediated effect, we performed the above experiments in the presence of antagonists specific for these receptors (Fig. 4A ). In the presence of the PPAR antagonist, GW9662, Rosi treatment did not result in increased GR phosphorylation, thus suggesting PPAR dependence.
Also, the effects of Pio were inhibited to some extent by GW9662. No differences were observed in the presence or absence of GW9662 with Dex alone or combined treatments, suggesting that PPAR is not involved in the GR phosphorylation in response to Dex.
As expected, the GR antagonists, RU486 and CORT108297, inhibited the phosphorylation of the GR in response to Dex alone or to the combination treatments (Fig. 4A ). RU486 and CORT108297 by themselves increased GR phosphorylation moderately; consistent with the known partial agonistic properties of these drugs (see Materials and Methods). This increased GR phosphorylation in response to the GR antagonists may obscure possible effects resulting from Rosi or Pio alone treatments. Therefore, it is difficult to conclude if phosphorylation of the GR in response to Rosi and Pio is dependent on GR signaling or not.
In summary, our data suggest that the phosphorylation of GR in response to Rosi, and possibly Pio, is PPAR-dependent, and that GR phosphorylation by Dex alone or in combination with Rosi and Pio requires GR-signaling.
In a separate experiment we determined the time course of the increase in phosphorylation of the GR at Ser211 in response to the Dex, Rosi, and Pio by semi-quantitative evaluation of the corresponding immuno-blots (Fig. 4B) . In order to estimate the changes in the relative degree This article has not been copyedited and formatted. The final version may differ from this version. of phosphorylation of the GR, the signals for phospho-GR were related to those of total GR.
Treatment with Dex greatly increased GR phosphorylation in a time-dependent manner.
Treatment with Rosi and Pio also resulted in increased GR phosphorylation, although to a lesser extent. Pio seemed to induce an early response with no further increase in the relative phosphorylation of the GR after 0.5 h.
Rosi and Pio Induce and Enhance the GR Transcriptional Activity in Podocytes.
Given our observations that TZDs are able to both protect podocytes and stimulate the GR, although to a lesser extent than Dex, we examined the ability of Rosi and Pio to regulate the transcription of two well-studied GC-responsive genes, FKBP51 and GILZ (Ayroldi and Riccardi, 2009; Vermeer et al., 2003) . FKBB51 is commonly associated with the GR complex and tends to inhibit its activity, while GILZ is a transcription factor controlling the expression of many other genes in response to GCs. Dex increased the mRNA expression of FKBP51 ~10-15 fold and GILZ ~3-5 fold, as measured after 1 and 3 days of treatment, following either short-term or longterm treatments (Fig. 5A, B ). Rosi and Pio alone induced FKBP51 and GILZ mRNA expression (~2 fold) in both short-term (except for GILZ induction in response to Pio) and long-term treatments, as measured after 3 days. Both TZDs also enhanced the induction of FKBP51 and GILZ mRNAs by Dex, as seen in both short-term and long-term treatments for FKBP51 (3 days), as well as in short-term treatments for GILZ (1 day). Specifically, Rosi and Pio enhanced the induction of FKBP51 from ~10-15 fold by Dex alone to ~20 fold when used in combination after 3 days (Fig. 5A) . and PPAR-specific antagonists RU486, CORT108297 and GW9662 (Fig. 6 ). As expected, RU486 blocked the induction of FKBP51 and GILZ mRNAs by Dex, alone or in combination treatments. Moreover, there was no significant difference in FKBP51 expression between the Dex alone treatment and combined treatments with Rosi and Pio in the presence of RU486
Modulation of the GR Transcriptional Activity in Podocytes by
(unlike in the absence of the antagonist), suggesting that RU486 also inhibits any enhancing effects of Rosi and Pio on Dex-induced expression. Given the known non-specific antagonistic effects of RU486 on other nuclear receptors (e.g. the progesterone receptor), this GR dependence was further confirmed by measuring the mRNA expression of one of the studied genes, FKBP51, using the highly specific GR antagonist, CORT108297. Similar to RU486, CORT108297 blocked the induction of FKBP51 by Dex alone or in combination treatments.
Also, as observed with RU486, no significant difference was observed between the Dex alone treatment and combined treatments with Rosi and Pio in the presence of CORT108297 (unlike in the absence of the antagonist). While CORT108297 is a highly specific antagonist for the GR, it is also known to exert partial agonistic effects (R. Clark, Corcept Therapeutics, personal communication; also see Materials and Methods). This partial agonistic activity is reflected in the relatively high baseline expression of FKBP51 in the presence of CORT108297 (Fig. 6 ).
Finally, in order to determine the PPAR dependence, the effects of Rosi and Pio in the presence of the PPAR antagonist, GW9662, were also measured on the induction and enhancement of Dex-induced mRNA expression of FKBP51 (Fig. 6) . GW9662 blocked the induction of FKBP51 mRNA by Rosi as well as the Rosi-and Pio-mediated enhancement of Dex-induced increase in FKBP51 expression. Also, no significant difference was observed between the Dex alone treatment and combined treatments with Rosi and Pio in the presence of GW9662 (unlike in the absence of the antagonist). As expected, GW9662 did not significantly reduce the expression of FKBP51 induced by Dex alone. These data suggest that both the Taken together, the transcriptional activity of the GR in podocytes can be modulated by both Rosi and Pio, and this modulation involves both GR and the PPAR signaling.
Rosi and Pio Have Disparate Effects on Dex-Induced Activity of Minimal and Native
Endogenous Promoters. To further examine the direct effects of Rosi and Pio on GR transcriptional activity, we analyzed the luciferase reporter activity under the control of a minimal promoter containing 4 GRE repeats (GGTACATTTTGTTCT) in HEK293T cells (Fig. 7A, B) .
Although Dex activated the promoter strongly, we did not observe major effects by Rosi or Pio in activating the luciferase gene expression driven by the minimal GRE promoter. Similarly, both
Rosi and Pio, in combination with Dex did not exhibit major effects on Dex-induced activation of this promoter, in both short-term and long-term treatments.
Since we had previously seen enhancing effects on endogenous gene expression in podocytes when these drugs were used in combination (cf. Fig. 5 ), we chose to explore if the absence of enhancement effects were due to the different cell types used, or if they were dependent on promoter specificity. We therefore analyzed the expression of the endogenous genes, FKBP51 and GILZ, in HEK293T cells treated with Rosi, Pio and/or Dex (Fig. 7 C, D) .
We observed that Rosi or Pio alone significantly induced the expression of both FKBP51 and GILZ. Dex, as expected, also induced the expression of these genes. Combined treatments with Rosi showed enhancing effects on Dex-mediated activation of these endogenous promoters, as was also shown in podocytes in Fig. 5 . Combined treatment with Pio enhanced the Dex-mediated activation of FKBP51. These observations are in accordance with earlier studies in which Rosi had an inhibitory effect on Dex-mediated activation of a simple promoter (TAT3) (Matthews et al., 2009) , whereas it enhanced Dex-mediated activation of the natural and more complex MMTV promoter (Johnson et al., 1999) .
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Discussion
The TZDs, Pio and Rosi, are widely used FDA-approved drugs for the treatment of Type II diabetes that have also been shown to reduce proteinuria and urinary podocyte loss in patients with diabetic nephropathy and non-diabetic glomerulosclerosis (Sarafidis et al., 2010) . We hypothesized that these renal protective effects of TZDs result, at least in part, from a direct action on podocytes. We found that both Pio and Rosi were indeed able to directly protect podocytes, similar to Dex, against experimentally-induced injury designed to mimic NS.
Additionally, we observed that Rosi and/or Pio were able to modulate the podocyte GR pathway and alter MAPK activation, as illustrated in Figure 9 . We also found that Rosi, Pio and Dex induced common, as well as selective, molecular signaling effects in podocytes. Together, our findings suggest that Pio and Rosi may have potential clinical utility as either a primary or adjunctive therapy for NS, or other diseases treated with GCs. Moreover, these findings may also lend new mechanistic insight into the well-established, but poorly understood renal protective effects of TZDs in diabetic nephropathy (Lennon et al., 2009 ).
Healthy podocytes contain an extensive network of actin filaments, with high content in the distal foot processes that attach to the underlying glomerular basement membrane (Smoyer and Mundel, 1998) . During NS, podocyte injury results in rearrangement of the actin cytoskeleton in the foot processes (effacement), and in some cases apoptosis, cell proliferation or dedifferentiation. Podocytes typically respond to stressors (e.g. treatment with PAN, shear stress) with reorganization or loss of filamentous actin, focal adhesions, or cell-cell contacts. In cultured podocytes these changes can be prevented by treatment with GCs or by ectopic expression of protective genes (Ransom et al., 2005) . In the present study, we found that, similar to GCs, TZDs can directly protect podocytes from PAN-induced injury, both in terms of cell viability and disruption of the actin cytoskeleton.
TZDs act as PPAR ligands, but are becoming increasingly known to mediate a portion of their actions through PPAR-independent pathways (Gardner et al., 2005; Ialenti et al., 2005) .
This article has not been copyedited and formatted. The final version may differ from this version. Additionally, it has been reported that minor differences in the chemical structure of Rosi and Pio may result in marked and distinct differences in their molecular, biological and pharmacological responses (Gervois et al., 2007; Kintscher, 2008) . Given these selective effects of Rosi and Pio, and the PPAR-independent effects of TZDs in general, we explored the ability of Rosi and Pio to modulate two of the major signaling pathways (MAPK and GC pathways) most relevant to podocyte protection in various renal diseases, including NS (Grande and Lopez-Novoa, 2008; Guess et al., 2010; Ransom et al., 2005) .
The MAPKs have been implicated in the progression of various glomerulopathies, and their inhibition is emerging as a promising therapeutic area for renal diseases, as well as for steroid resistance in other diseases (Bloom, 2004; Grande and Lopez-Novoa, 2008) . Given the importance of MAPK signaling in renal diseases, we were also interested in determining the ability of TZDs to modulate the various MAPKs in podocytes, and in comparing these results to those of GCs. We found that Rosi deactivated ERK1/2, p38 MAPK and SAPK/JNK. While Dex also seemed to deactivate ERK1/2 and possibly p38 MAPK, Pio did not have any notable effects. Inhibition of p38 MAPK and possibly ERK1/2 in PAN and adriamycin animal models of NS has been reported to suppress proteinuria and actin reorganization in podocytes (Koshikawa et al., 2005) . In addition, we have shown that inhibiting either p38 MAPK or its downstream substrate MK2 prevents PAN-induced injury to podocytes (Pengal et al., unpublished) .
Increased amounts of activated ERK and p38 MAPK have also been reported in the glomeruli of patients with diabetic nephropathy (Sakai et al., 2005) .
GCs are the prevailing therapy for NS and are also known to act directly on podocytes, although not much is known about their mechanism of protective action (Guess et al., 2010; Ransom et al., 2005) . We studied the effects of TZDs on the GR pathway in podocytes and found that Rosi and Pio phosphorylate the GR at the site associated with its activation, although to a lesser extent than Dex. In support of this finding, other recent reports have also linked the action of TZDs to the GR pathway (Ialenti et al., 2005; Matthews et al., 2009) . In these studies, the anti-inflammatory effects of Rosi and ciglitazone were shown to involve, to some extent, GRdependent signaling. Additionally, TZDs were shown to activate nuclear translocation of the GR in vitro, with no effect on its down-regulation and independent of the PPAR. Similarly, in the present study Rosi and Pio did not lead to down-regulation of the GR, which is a known negative feedback mechanism associated with GC treatment. Theoretically, such an effect could be clinically beneficial if TZDs were used in patients with steroid-resistant NS (or other steroid resistant diseases), since it might overcome this known negative feedback mechanism.
Furthermore, we found that the phosphorylation of GR by Rosi and possibly Pio is PPAR dependent as it is abolished in the presence of GW9662, a selective PPAR antagonist. This suggests that the PPAR may interact with the GR signaling pathway by physical or co-factor dependent interaction upon activation as has also been shown recently in other systems (Lahiri et al., 2009; Nie et al., 2005) .
Given the complex nature of both GR-and PPAR agonist-mediated signaling, the interplay of transcription co-factors (activators or repressors) can be assumed to be altered by PPAR agonists. Such crosstalk among signaling cascades may be the basis for the synergistic effects on GR signaling exerted by Rosi and Dex in a mouse model of inflammation, or for their ability to modulate Dex-as well as Rosi-induced gene transcription and differentiation in osteoblastic cells (Ialenti et al., 2005; Johnson et al., 1999) . In the latter report, Rosi did not exhibit any effect alone in activating the native MMTV promoter, whereas it enhanced the effects of Dex on the same promoter. In a different report, Rosi and Pio minimally activated a GRE TAT3
promoter, but repressed its activity when used in combination with Dex (Matthews et al., 2009 ).
In the current study using a minimal GRE promoter with 4 GRE sites, combination treatments using Rosi or Pio with Dex did not significantly alter the GRE promoter activity. Despite this, Rosi and Pio both induced the expression of two endogenous GC-responsive genes, GILZ and FKBP51, and also enhanced Dex-induced expression of these genes. These findings, together with the above reports, suggest that the effects of TZDs on Dex-regulated gene expression can be very disparate, depending on the nature of the studied promoters and genes. Moreover, our findings that GR phosphorylation by Rosi and possibly Pio is PPAR mediated, and that both TZDs modulate GR-responsive genes in podocytes in a PPAR-and GR-dependent manner suggest that these drugs are indeed able to modulate GR signaling in podocytes, and that their protective effects could possibly be mediated in part via these pathways.
Lastly, since CaN inhibitors are often used as alternative treatments for NS, we investigated the ability of TZDs to alter CaN activity in podocytes. We also compared their modulation of CaN activity to that of Dex, since GCs are known to provide direct protection to podocytes against injury. Of particular note, we found that all three drugs which protected podocytes against PAN-induced injury (Pio, Rosi, and Dex) also increased the phosphatase activity of CaN in these cells. This finding is consistent with a previous report of transcription-independent activation of CaN by GCs in renal proximal tubular cells (Tumlin et al., 1997) . However, our findings of increased podocyte CaN activity in response to Rosi, Pio and Dex were somewhat surprising, since CaN inhibitors (cyclosporine and tacrolimus) are widely used clinically to treat steroid dependent and steroid resistant NS. Moreover, CaN inhibition has been suggested to be involved in cyclosporine's direct effects on podocytes via stabilization of the actin cytoskeleton (Faul et al., 2008) . Despite this, the current findings suggest the possibility that inhibition of podocyte CaN activity may not be critical for the clinical efficacy of cyclosporine and tacrolimus in NS. Thus, while the role of podocyte CaN activity in response to injury remains unclear at this time, our results suggest yet another similarity between the molecular actions of GCs and TZDs in podocytes.
In summary, we have found that TZDs are able to modulate the GC pathway and exert direct protective effects on podocytes, similar to GCs, possibly via previously unrecognized effects on GC and MAPK signaling. These findings suggest that these FDA-approved drugs This article has not been copyedited and formatted. The final version may differ from this version. lysates were subjected to SDS-PAGE followed by immuno-blot analysis for phosphorylated (p-GR) and total GR, and for GAPDH. Representative blots from 3 independent experiments are shown. B, Cells were treated with Rosi, Pio and Dex as in A, harvested at 0 h (control), 0.5 h, 2 h and 4 h, and subjected to immuno-blot analysis.
Densitometric analysis was performed and the ratios of the phosphorylated and total GR were plotted as fold increases relative to the control (indicated by the dotted line). The sequences are in 5' to 3' orientation.
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